Illumina Aims for Single-Molecule Sequencing, Launches New Business Unit for the Clinical Market | GenomeWeb

By Monica Heger

is working on a single-molecule sequencing technology, CEO Jay Flatley said today at the JP Morgan Healthcare Conference in San Francisco.

Flatley also discussed a number of other technologies that the company has in its pipeline, as well as a new business unit it has formed to focus on the clinical market, and how he sees the next-gen sequencing market growing over the next few years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.